The alcohol research field has amassed an impressive number of gene expression datasets spanning key brain areas for addiction, species (humans as well as multiple animal models), and stages in the addiction cycle (binge/intoxication, withdrawal/negative effect, and preoccupation/anticipation). These data have improved our understanding of the molecular adaptations that eventually lead to dysregulation of brain function and the chronic, relapsing disorder of addiction. Identification of new medications to treat alcohol use disorder (AUD) will likely benefit from the integration of genetic, genomic, and behavioral information included in these important datasets. Systems pharmacology considers drug effects as the outcome of the complex network of interactions a drug has rather than a single drug-molecule interaction. Computational strategies based on this principle that integrate gene expression signatures of pharmaceuticals and disease states have shown promise for identifying treatments that ameliorate disease symptoms (called in silico gene mapping or connectivity mapping). In this review, we suggest that gene expression profiling for in silico mapping is critical to improve drug repurposing and discovery for AUD and other psychiatric illnesses. We highlight studies that successfully apply gene mapping computational approaches to identify or repurpose pharmaceutical treatments for psychiatric illnesses. Furthermore, we address important challenges that must be overcome to maximize the potential of these strategies to translate to the clinic and improve healthcare outcomes.
Introduction
Developing more effective pharmacotherapies to treat disease is an important goal in public health. This is especially true for complex psychiatric diseases like alcohol use disorder (AUD), where there are limited pharmaceutical treatment options. We use AUD throughout this review for consistency as this is the terminology used in the current edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM5), but this does not exclude previous DSM version diagnostic criteria or preclinical/clinical trials based on those. AUD is a chronic, relapsing disease that devastates individuals, families, and society and is a major public health problem. Though recovery is possible regardless of disease severity, there are few pharmaceutical treatments available to aid in the recovery process. There are several points of intervention along the time course of AUD where pharmacotherapies might be effective, including AUD initiation (initial alcohol use), development (sporadic intermittent alcohol use; the binge-intoxication phase), progression (regular use), early abstinence (the withdrawal-negative affect stage) or protracted abstinence (the preoccupation-anticipation (craving) stage) (Koob et al. 2009; Kreek et al. 2002) . Sleep disturbances are a key contributor to relapse in abstinence and therefore offer another target for treatment (Brower 2015; Miller et al. 2017) . Therapeutic interventions at any point along this continuum could improve the health of the individual.
Pharmaceutical treatments can either be developed de novo for a specific drug target, repurposed, or rescued. While the usage and definition of the terminology Bdrug repurposingâ nd Bdrug rescue^can be complex (Langedijk et al. 2015) , here we define drug repurposing as finding a novel clinical use for an approved drug and drug rescue as finding a clinical use for a stalled drug (whether the drug is in development but not yet approved or failed for one indication but could be useful for another disease or patient subgroup; phase 2 or beyond). Drug repurposing (also referred to as drug repositioning) is appealing because it reduces the overall costs of drug development and expedites the availability of treatments to those who need them (Nosengo 2016) . Drug repurposing has largely centered around side-effect data, and, while this approach has been somewhat successful for brain diseases, there is a great need for improved strategies for drug selection. De novo drug development has traditionally relied on target identification through basic research. Over four decades of alcohol research has identified key neurotransmitter systems and brain regions that contribute to the various stages of AUD pathology and represent potential targets for pharmaceutical development. Despite these advancements, there has been sparse translational success clinically. There are only three FDA approved drugs for AUD: naltrexone (oral: ReVia®, injectable: Vivitrol®), acamprosate (Campral®), and disulfiram (Antabuse®), the most recent of which, acamprosate, was approved in 2004. This gap between advances in basic research (conducted primarily at academic institutions) and pharmaceutical development (primarily undertaken by industry, e.g., pharmaceutical companies) has been dubbed the Bvalley of death^ (Butler 2008) .
The explosion of both the quantity and availability of various types of molecular datasets (e.g., gene sequence/ genotype, gene expression, epigenetic marks, metabolic measures) and computational strategies to exploit them, offers new solutions to this problem and is moving disease diagnosis and treatment into the molecular realm. Many computational (or in silico) strategies exist, and all are concerned with finding the Bsimilarity^between diseases and drugs. The computational strategies highlighted in this Review involve integrating molecular profiles of a disease state with those of pharmaceuticals to predict effective treatments. Molecular profiles can be derived from multiple molecular phenotypes, including gene expression, protein targets (see the issue in this article for proteome targets in the accumbens by Clyde Hodge and colleagues), genetic variants (single nucleotide polymorphisms (SNPs)), and others, though the focus of this review will be on gene expression. Another approach to computational repurposing uses crystal structures of receptors to conduct structurebased ligand discovery (Heusser et al. 2013) . In this review, we focus on the aforementioned computational approaches and will not discuss structure-based ligand discovery in detail, but interested readers are referred to a review (Howard et al. 2014 ).
Traditional approach

Drug development
Disease-related drug development begins with mechanistic studies of target identification followed by validation (see the review in this issue by Ciccocioppo and colleagues for an in-depth discussion of target validation), preclinical and clinical trials, and FDA review. Typically, a single cellular or molecular target is sourced from the results of much neurobiological research (Fig. 1) . Despite clear scientific evidence for its involvement in disease pathology at multiple levels of analysis (e.g., molecular, neuropharmacological, neurocircuitry, behavior), the single target approach has largely been a failure for brain diseases (Hutson et al. 2017) . A striking example of this is for Huntington's disease, where the single causative gene (HTT) has been known since 1993 (MacDonald et al. 1993) . Despite this single, well-validated target, no drug nor therapeutic options have been developed as treatments. One example of this for AUD is the corticotrophin releasing factor (CRF) system, which has tremendous research support for its involvement in AUD pathology, yet CRF inhibitors have produced disappointing results in double-blind, placebocontrolled trials (Kwako et al. 2015; Pomrenze et al. 2017; Schwandt et al. 2016) .
Despite the vital insights gained from neurobiological research (both in humans and animal models), these findings have not translated into therapeutic success. There are a number of possible reasons for this, including genetically heterogeneous human populations and the complexities of alcohol's many targets Pomrenze et al. 2017 ). The brain is highly complex, and psychiatric diseases are characterized by numerous symptoms. Reducing this complexity to a single target is appealing for its simplicity but perhaps misguided, and expecting modulation of a single gene or molecule to ameliorate all symptoms of complex diseases is likely to produce disappointing results.
Targets (molecules) do not work in isolation, but function as part of a system (or network) to accomplish biological functions. The hypothesis that a disease state represents a shift from normal physiological homeostasis and can be thought of as a network perturbation has been proposed and described in detail, and is attractive for several reasons (Barabasi et al. 2011; Chen and Butte 2013; Jacunski and Tatonetti 2013; Kolodkin et al. 2012; Silbersweig and Loscalzo 2017; Silverman and Loscalzo 2013) . First, there could be many network perturbations that lead to the same disease classification, which fits with the heterogeneous patient populations we observe in AUD. Secondly, the other side of this argument is that if a disease represents a perturbed state of a biological network, there could be multiple pharmacological intervention points to reverse those perturbations and return the system to homeostasis. Targeting the network at several points might be more efficient (or even necessary) to shift the system back to normal homeostasis. This also provides a basis for polypharmacology (the use of drug combinations to treat a disease) and could guide the selection of drug combinations, which will not be discussed in depth in this review, but interested readers are referred to Ryall and Tan (2015) for more information. For these reasons, we and others propose that to maximize the likelihood of successful treatment for complex disorders, it is imperative to Bdrug the network^rather than focus solely on single targets (see BComputational approaches^section).
Drug repurposing
Traditionally, getting a drug to market takes 13-15 years and costs 2-3 billion dollars on average (Nosengo 2016) . Many drugs that are currently FDA approved could be beneficial for diseases other their original indication. Additionally, pharmaceutical companies have invested considerable resources into developing drugs that passed initial safety trials but failed in efficacy trials (sometimes referred to as shelved compounds) that are waiting for a suitable indication (Nosengo 2016) . Often, successful drug repurposing has been serendipitous ( Fig. 1 ). There are many examples spanning a variety of conditions, from the classic example of sildenafil (Viagra®), a PDE5 inhibitor being developed for hypertension, that was repurposed for erectile dysfunction (Goldstein et al. 1998) , to bimatoprost (Lumigan®/Latisse®), a prostaglandin analog that was repurposed for a cosmetic application as it was noticed to lengthen and darken the eyelashes as a side effect of those using it to treat glaucoma (Tosti et al. 2004) .
Drug repurposing has also been successful for brain diseases. For example, buprenorphine, a mixed partial agonist opioid receptor modulator, was originally used for pain relief and was repurposed to treat opiate dependence (Jasinski et al. 1978) . Ropinirole (Requip), a dopamine agonist used an antiParkinson's agent, was repurposed for treatment of both restless legs syndrome and SSRI-induced sexual dysfunction (Cheer et al. 2004; Worthington et al. 2002) . Additional examples include bupropion (depression to smoking cessation) (Lief 1996) , dimethyl fumarate (psoriasis to multiple sclerosis) (Bomprezzi 2015) , and guanfacine (hypertension to ADHD) (Strange 2008).
Several FDA approved or shelved compounds have shown promise in treating AUD and many are currently undergoing human lab testing or are in clinical trials (ClinicalTrials.gov_AUD), including gabapentin, topiramate, varenicline, ABT-436, mifepristone (RU-486), citicoline, baclofen, nalmefene, and others (Litten et al. 2016; Lyon 2017) (Table 1) . Gabapentin (Neurontin) was initially used as an anti-epileptic, then later approved for neuropathic pain and amyotrophic lateral sclerosis. Baclofen (Liorsel) is a GABA B receptor agonist, originally made as an anti-epileptic with disappointing results, but showed remarkable effectiveness for treating spasticity in many conditions, especially for spinal cord injury, cerebral palsy, and multiple sclerosis. As mentioned, it is being considered for treatment of AUD (with mixed findings) (Farokhnia et al. 2017) . Fig. 1 Traditional approach to drug discovery and drug repurposing: existing knowledge of a disease state (built upon basic science) is applied to select a compound designed for a single target (chosen for its involvement in a disease process), and these are tested in vitro and/or in vivo. Brain gene expression levels (Brain Omics) are measured for drugs that ameliorate disease phenotype which helps further elucidate the mechanisms of action (MOAs) of drugs and suggests other molecules that can be targeted by candidate drugs. Traditionally, drug repurposing (finding new indications for existing compounds) has been largely based on side effect data, adverse events, existing literature, or structural similarity between compounds used to treat different diseases (the idea being that the compound of one disease might be able to treat another because it shares structural similarity with compounds used to treat that disease). Drug repurposing efforts would benefit greatly if there was a system established to report positive side effects as is the case for Badverse events.^Capsule images from http://smart.servier.com/category/generalitems/drugs-and-treatments/. Servier Medical Art by Servier is licensed under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) Schotte et al. (1996) , and Litten et al. (2012) Aripiprazole ( Geisler and Ghosh (2014), Guglielmo et al. (2012) , Litten et al. (2016 ), Mason et al. (2014a , and Nunes (2014) Borro et al. (2016) , Colombo et al. (2004) , Farokhnia et al. (2017) , Geisel et al. (2016) , Imbert et al. (2015) , Litten et al. (2016) , Liu and Wang (2017) , Lyon (2017) , Mirijello et al. (2015) , Morley et al. (2014 ), Muller et al. (2015 , Ponizovsky et al. (2015) , Rigal et al. (2015) , Rolland et al. (2015a, b) , and Weibel et al. (2015) Nalmefene ( 
Computational approaches
The generation and accumulation of publicly accessible, highthroughput genomic datasets make it possible to integrate largescale drug and disease signatures at the molecular level to predict compounds with the potential to treat a disease based on multiple targets (e.g., gene networks). These data-rich resources include public repositories (primary archives), integrative databases, and value-added databases (these tools are designed to process, analyze and annotate complex information from primary data sources to lower the computational barriers to access primary data). A selection of these resources is summarized in Table 2 . There are two essential datasets from these resources that are required to match disease and drug: (1) measurements of a molecular phenotype induced by a disease state and (2) measurements of the same molecular phenotype induced by drugs. Obtaining this type of reliable drug library is not trivial. Surprisingly, attaining a list of approved drugs and their indications is not a straightforward task. These difficulties are the result of poor data storage and electronic retrieval mechanisms, complex and rapidly changing nomenclature (drugs can be called by their common name, chemical name, simplified molecular-input line-entry system (SMILES), International Chemical Identifier (InChI)), and legal issues surrounding off-label advertisement of pharmaceuticals. Fortunately, many of these challenges have been overcome largely by the pioneering work by a collaborative effort of the Broad Institute and funding from a National Institutes of Health Common Fund (https:// commonfund.nih.gov/lincs). They have compiled the Lib rary o f Integra te d N etwork-ba sed Cellular Signatures (LINCS-L1000) database which contains gene expression responses to genetic and pharmacologic manipulation across a diverse set of human cell lines . They also maintain a repurposing hub that contains over 5000 manuallycurated drugs that are either FDA approved or in clinical trials . The availability of these tremendous resources is a primary reason we focus on gene expression as the molecular phenotype, as other molecular responses to drugs are not as well characterized in such a systematic manner or as accessible for analysis. With the two required datasets described above, there are three main steps to proceed from gene networks to candidate compounds (see Fig. 2) , which then can be tested in a preclinical animal model or human laboratory study:
1. Generate an input signature that captures the genomic state of interest (gene expression differences between disease and healthy state, for example).
2. High-throughput identification of compounds using an in silico screen (similarity metric). 3. Prioritize candidate compounds.
The details of each step are described below.
Generate an input signature that captures the genomic state of interest
The purpose of the signature is to capture the molecular changes that are the most relevant to the biological state of interest at a given point in time. There are many different options for constructing an input signature. Applying such approaches to brain diseases is still in its infancy and understanding the optimal input parameters is a major challenge (see the BChallenges and future directions^section below). Genetic variation (genotyping or exome/whole genome sequencing data) has been the primary approach used for genomic medicine/precision medicine for cancer (Letai 2017) . A functional genomic measure, such as gene expression can also be used. This is referred to as in silico gene mapping, gene mapping, or connectivity mapping, the latter named after one of the first characterizations of the method using the Broad Institute's database called the Connectivity Map (CMap) (Lamb et al. 2006) . Importantly, the AUD research field has generated an incredible library of gene expression data that spans multiple species (human, mouse, monkey, rat), conditions/treatments (genetic predisposition, various acute or chronic ethanol exposures, or paradigms), various brain regions, and isolated cell types (including microglia and astrocytes) ( Table 2) .
High-throughput identification of compounds using an in silico screen (similarity metric)
At their core, the various approaches used for in silico gene mapping aim to compare drug and disease signatures. If an effect size measure (such as fold change) is available, a correlation coefficient could be calculated, to reflect the correlation between gene expression changes between drug and vehicle and those between disease and normal. Positive correlations would indicate that the drug mimics the disease's effects on transcription levels, while negative correlations would indicate that the drug reverses it. An alternative approach is to use an enrichment score to assess the overlap between two lists of differentially expressed genes, such as the hypergeometric statistic or the rank-based gene set enrichment analysis (GSEA; corresponds to a weighted KolmogorovSmirnov) (Subramanian et al. 2005 ). For example, list A contains the top differentially expressed genes between disease and healthy samples, and list B contains the top differentially expressed genes between drug and vehicle samples. The Napolitano et al. (2016) hypergeometric statistic would give the probability of the overlap between list A and list B (the genes changed by both drug and disease). GSEA, the approach implemented by the Connectivity Map (CMap) and LINCS-L1000, avoids using arbitrary cutoffs (the p value which designates differential expressions between two conditions or treatments) by genenetwork.org/webqtl/main.py Mulligan et al. (2017) considering all of the genes in an experiment. Ranked methods for the hypergeometric test have also been described and offer the same benefits as GSEA (Plaisier et al. 2010) .
Prioritize candidate compounds
Regardless of which statistical test is chosen, the output of the previous step will include a list of predicted compounds with a corresponding similarity score (also called a connectivity score). Because only a handful of drugs can be tested in vivo, this list must be filtered to select the most promising candidate compounds. The working hypothesis is that negative scores would predict reversal of gene expression from disease back to normal state. However, this hypothesis is rarely tested directly (see BChallenges and future directions^), though it does have some support (Chen et al. 2017; Delahaye-Duriez et al. 2016; Wagner et al. 2015) . Regardless, drugs with either the highest absolute value or the most negative similarity scores should be prioritized, as these reflect the drugs that affect the most disease-related genes.
Beyond the sign (+/−) and magnitude of the connectivity score, there are additional practical considerations for prioritizing candidate compounds (Oprea and Overington 2015) . For example, any identified high-priority candidate drugs for AUD treatment would also benefit from having (1) known oral dosing data available, (2) have little or no safety warnings (especially regarding liver toxicity), (3) have low abuse liability, (4) low drug-drug interaction potential, (5) negligible cytotoxic actions, and (6) high brain penetrability, among others. These considerations alone will assist in narrowing the pool of potentially Btestable^compounds considerably, if the information is available (which is frequently not the case). Upon first glance, it might seem that the challenge is selecting only a few compounds from hundreds of candidates generated by in silico screens to test clinically or preclinically. However, this is not the case. Meeting the ideal practical considerations outlined above could eliminate virtually all candidate compounds (Oprea and Overington 2015) . In that case, medicinal chemistry approaches could be used to modify the chemical structure to suit the desired product profile. Fig. 2 Computational approach to drug discovery and drug repurposing: disease state can be either acquired (disease or substance of abuse changes gene networks and these changes drive disease) or predisposed (genetic variants cause disruptions in gene networks). The goal of in silico gene mapping is to integrate the targets (gene networks) of disease and drugs to find a drug (or combination of drugs) that affect similar targets as the disease. Drugs that oppose the disease-state's molecular disruption (many targets) are chosen as candidate compounds to ameliorate disease phenotype. There are three steps to go from gene expression datasets to candidate compounds: (1) generate an input genomic signature or network. Shown is a gene-gene coexpression network of genes related to a disease state: nodes = genes, edges = gene-gene expression correlation, yellow = up-regulated genes, blue = down-regulated genes; (2) compare the disease signature to those induced by drugs to identify drugs that would reverse the disease signature. Shown are the effects of three different drugs in the reference database (e.g., LINCS-L1000) on the disease-related genes that served as the input and (3) prioritize candidate compounds for in vivo testing. The blue drug that received a perfect negative score would be prioritized because it down-regulated the genes that were up-regulated in the disease state and up-regulated the genes that were down-regulated in the disease state. The yellow drug would be predicted to mimic or worsen the disease state. Had the input been a desirable biological state (e.g., the gene expression profile of patients with AUD who had prolonged recovery vs. those who relapsed quickly after ceasing alcohol consumption), then the yellow drug would be prioritized because it is predicted to mimic the beneficial biological state. Capsule images from http://smart.servier.com/category/general-items/drugs-andtreatments/. Servier Medical Art by Servier is licensed under CC BY 3. 0 (https://creativecommons.org/licenses/by/3.0/). AUD, alcohol use disorder Drug prioritization should also depend on the reliability of the analytical results. That is, the connectivity score should be reproducible for strong candidates. This is especially important to consider because small changes in the genes that makeup the input signature can result in the identification of different candidate compounds. The above-mentioned CMap database utilizes a statistical measure of reliability (permutation test) to achieve this goal. Stricter statistical measures have also been developed for CMap. For example, the statistically significant connectivity map (ssCMap) was developed (Zhang and Gant 2009) , which includes a measure of stability by removing single genes from the input in a systematic manner and assessing reproducibility (McArt and Zhang 2011) . However, for larger datasets, such as LINCS-L1000, implementation of permutations tests becomes computationally expensive and less straightforward. Currently, the web app for querying the LINCS-L1000 data (https://clue. io/l1000-query) uses the Bsig_gutc^tool to summarize the connectivity scores and provide a measure of reliability. Each compound has been profiled under multiple experimental conditions (different cell lines, drug doses, and exposure time points). To attain a compound-level analysis, sig_ gutc reports a summary score of the distribution of scores for a compound across all experiments. The tool then ranks the connectivity score between the query signature and the compound signature, based upon the compound's precomputed distribution of connectivity scores with the other hundreds of thousands of signatures in the LINCS-L1000 database. This provides a measure of the likelihood of a connectivity score for a drug given that drug's connectivity with the database as a whole, thus mitigating false positives from drugs with widespread effects on transcription. However, an appropriate statistical framework with which to interpret LINCS-L1000 results needs to be developed.
Application to brain diseases
While initially used in cancer research (for review, see Chen and Butte 2016) , these computational repurposing strategies have also been applied to brain diseases, albeit in a more limited capacity. However, it should be noted that although not used as widely, the studies using these computational approaches for drug discovery for brain diseases have provided promising leads for variety of disease states. Because there are few applications so far for psychiatric disorders, this review includes the use of in silico gene mapping strategies for any disease in which brain is the primary affected organ, for which there have been 20 studies so far to the best of our knowledge (Table 3) .
Regarding the construction of the input genomic signature, the studies fall into two main categories: those that use genotype data (i.e., SNPs related to a disease phenotype discovered from genome-wide association studies (GWAS)) and those that use gene expression data. Gene expression measurement technology (RNA sequencing or microarray) provides the expression levels of all genes in the genome simultaneously, supplying a functional genomic readout of the effects of the combination of the genetic variants that could be contributing to disease. Gene expression is by far the primary input used by the studies in Table 3 , the idea being to compare the gene expression levels between disease and healthy tissue and to use the top differentially expressed genes as the input signature, as this is thought to best capture the molecular differences driving disease phenotypes. However, there is no consensus on the optimal threshold or number of differentially expressed genes to use. Differentially expressed genes can be subdivided into groups of genes with highly correlated expression levels. Indeed, several studies incorporate gene co-expression networks or protein-protein interaction networks to refine the genomic input signature (Chandran et al. 2016; Delahaye-Duriez et al. 2016; Gao et al. 2014) . One study compared the performance of using only differentially expressed genes between Parkinson's and normal brain to query CMap versus a combined approach that used both differential expression and gene co-expression network information (Gao et al. 2014) . They calculated the number of known Parkinson's therapeutics in the top 50 ranked compounds from each approach. Using the top 20 genes from the combined method outperformed using the top 20 genes from differential expression alone. They were not able to assess the performance of using only the gene co-expression network as a query for lack of up-regulated genes in the co-expression module. Interestingly, using more than the top 20 genes from the combined approach led to a decrease in performance. Because gene coexpression network modules are driven by variability in the data, and cell type is a major contributor to gene expression variability, it is possible that network based approaches could be more useful for diseases that primarily affect a specific cell type (like in the case for Parkinson's disease). One downside of using gene expression data is that human brain tissue can only be obtained postmortem and the transcriptional signature can be confounded by a lifetime with the disease or pharmaceutical management of the disease (see BChallenges and future directions^).
Genotype/gene sequence data, on the other hand, is readily available, easy to attain, and is relatively static throughout the patient's lifetime, but it is not without its drawbacks. Many genes contribute to the genetic risk of most complex psychiatric disorders, each contributing a small effect. A minority of diseaseassociated SNPs are mapped to protein-coding regions of the genome, and there are few drugs that specifically target particular gene products. Despite these challenges, Papassotiropoulos et al. (2013) used intragenic SNPs related to aversive memory performance to select the antihistamine, diphenhydramine, as a potential drug that would reduce aversive memory recall (Papassotiropoulos et al. 2013 ). This was verified in a double-blind, placebo-controlled, cross-over study in which a single administration of diphenhydramine (50 mg) compared with placebo significantly reduced delayed recall of aversive, but not of positive or neutral, pictures.
Most disease-associated SNPs, however, occur in non-coding regions and their impact on disease outcome is difficult to Instead use clue. io/l1000-query) Chang et al. (2017) . The approach relied on an algorithm called MetaXcan (Barbeira et al. 2016) , which incorporated GTEx data to build statistical models for predicting expression levels from SNPs in a reference transcriptome dataset, and these prediction models were used to impute the expression z-scores (i.e., z-statistics derived from association tests of expression changes with disease status) based on GWAS summary statistics. Transcriptome profiles were imputed for seven psychiatric conditions based on GWAS summary statistics and compared with drug-induced changes in gene expression using CMap to identify potential treatment candidates. Novel compounds were not tested; however, it was promising that the top 15 predicted compounds for some of the psychiatric disorders were enriched with known and predicted psychiatric medications according to several drug-disease indication measures (Anatomical Therapeutic Chemical (ATC) codes, ClinicalTrials.gov, MEDication Indication (MEDI) resource).
Once the input genomic signature is defined, it can be compared to a database of drug signatures. Most of the studies in Table 3 (13/20) use the original CMap database. The benefit of CMap is that it is smaller and simpler to perform statistics to assess a connectivity score's reliability. However, the trade-off is fewer drugs and cell lines, the latter of which is especially important for brain diseases because CMap contains no brain cell lines, whereas LINCS-L1000 contains two brain cell lines with considerable data, NEU and NPC. Unfortunately, at this time, these cell lines are not included in the implementation on their query app at clue.io; however, the LINCS-L1000 datasets can also be downloaded from Gene Expression Omnibus (GEO) (accession numbers GSE70138 and GSE92742). Efforts are underway to include more brain cell lines in the LINCS-L1000 database to facilitate its relevance to brain diseases (RDM, personal communication) .
To compare the disease and drug signatures, the KS-like statistic (as described by (Lamb et al. 2006; Subramanian et al. 2017 ) is the most frequently used similarity metric, although several studies also use Spearman or Pearson correlation coefficients (Azim et al. 2017; Siavelis et al. 2016; So et al. 2017 ) or Fischer's exact test (Delahaye-Duriez et al. 2016 ). Most studies operate under the transcriptional Breversal hypothesis,^which assumes that drugs with negative connectivity scores (i.e., with gene expression signatures that revert the disease's effects on gene expression to the control state) would ameliorate disease phenotype. Five of the 20 studies outlined in Table 3 have functionally validated this hypothesis, in that the candidate compounds ameliorated some disease phenotype when tested behaviorally (though none have confirmed that the beneficial effects of the compound were due to the restoration of gene expression to the Bnormal^state) (Chandran et al. 2016; Ferguson et al. 2017; Mirza et al. 2017; Papassotiropoulos et al. 2013; Smalley et al. 2016) .
These studies provide a functional rationale for prioritizing negatively-scoring compounds, i.e., those that have opposing effects on gene expression associated with the disease state. However, in addition to reflecting gene expression changes that drive the disease or represent deleterious aspects of a disease state, the differentially expressed genes between disease and healthy samples could also reflect protective homeostatic compensations within the system. Because some of the differentially expressed genes might be beneficial, it is reasonable to also consider drugs with high positive connectivity scores.
The rationale for the reversal hypothesis was tested directly utilizing a gene expression signature comprised of the top 100 differentially expressed genes identified in Huntington's disease (HD). Data were obtained from the caudate nucleus from disease vs. sex-and age-matched human controls followed by CMap query (Smalley et al. 2016) . The top 12 positive and negative scoring compounds were tested in in vitro caspaseactivation assays to assess the degree to which they modulated mutant huntingtin (HTT)-induced apoptosis in a PC12 cells. None of the positive scoring compounds affected caspase activity, while 7/12 negative scoring compounds decreased caspase activity, two of which had neuroprotective effects in vivo in a drosophila model of HD. This outcome supports the Breversal hypothesis.^However, because the caspase activity was approaching 100% (i.e., a ceiling effect), the ability to observe increased caspase activity precluded experimental outcomes predicted from positive scores that might mimic/worsen disease phenotypes (the converse of the reversal hypothesis).
One study does provide in vivo validation of the converse of the reversal hypothesis: that drugs with positive scores (i.e., with gene expression signatures that are similar the disease's effects on gene expression) would mimic the state of interest. Azim et al. (2017) sought to identify small molecules to mobilize endogenous stem cells and direct their fate as a therapy for neurodegenerative and demyelinating disorders (Azim et al. 2017) . These studies used the transcriptional signatures of neural stem cells (NSCs) in the ventral/lateral subventricular zone (SVZ) of the dentate gyrus which give rise to interneurons of the olfactory bulb and cortical areas, and of NSCs in the dorsal SVZ which give rise to glutamatergic neurons and oligodendrocytes. The authors prioritized positively-scoring compounds with the hopes that that would reproduce the lineage-specific transcriptional signatures. Indeed, the most promising candidates, LY-294002, an inhibitor of PI3K/Akt, promoted development of oligodendrocytes, and AR-A014418, an inhibitor of GSK3β, rejuvenated the NSC lineage. Furthermore, another GSK3β inhibitor promoted regeneration in a mouse model of hypoxic brain injury, by recruiting new oligodendrocytes and glutamatergic neurons into the cortex.
In addition to gene expression signatures of drug perturbation, the LINCS-L1000 database also catalogs gene expression response to genetic perturbation. One study utilized this resource and compared the input genomic signature to those of gene knockdown or overexpression in LINCS-L1000 to gain mechanistic insight into how morphine tolerance alters response to lipopolysaccharide (LPS) and found that VPS28 may be one of the genes responsible for the alterations associated with morphine tolerance (Chang et al. 2017) . In addition to looking at the negatively correlated drugs for treatment candidates, several studies also analyzed the positively correlated drugs for mechanistic insight into the disease, as these would be predicted to produce similar effects on gene expression and mimic or worsen disease phenotype Slonim et al. 2009 ).
Challenges and future directions
The CMap and LINCS-L1000 databases contain multiple experiments for the same compound. It is clear that the compound's effects on gene expression are greatly affected by variables such as cell line, dose, and time point at which gene expression is assayed (Chen et al. 2017) . Some researchers make no attempt to summarize across cell lines, doses, and time points to attain a composite compound-level view, which could lead to spurious results, particularly if the cell line is vastly different from the cellular makeup of the tissue used to generate the genomic signature used as the input query. For these reasons, we propose that using multiple expression datasets, algorithm parameter settings, and methods for prioritizing compounds (as taken by Ferguson et al. 2017; Gao et al. 2014; Guedj et al. 2016; Siavelis et al. 2016 ) are critical to identify an effective drug candidate, at least until proper gold standard datasets exist with which to benchmark the optimal settings (see below).
An important limitation of in silico gene mapping approaches is that they rely on comparisons of brain gene expression data to gene expression data from cell culture and are therefore constrained by the same limitations of any in vitro system. Brain gene expression is a complex combination of direct and indirect expression changes occurring in multiple cell types and brain regions. Even if brain-relevant cell lines were included in the expression profiles of LINCS-L1000 or other databases of drug-related transcriptomes, it is unclear how relevant in vitro results are to the biology of an intact organism, which is why in vivo experimental validation is critical. Only 6 of the 20 studies for brain disease listed in Table 3 performed in vivo validation of the proposed pharmaceutical candidates (Azim et al. 2017; Chandran et al. 2016; Ferguson et al. 2017; Mirza et al. 2017; Papassotiropoulos et al. 2013; Smalley et al. 2016 ), and none directly tested the underlying assumption of in silico connectivity mapping. Specifically, it is important to address the following question: if a candidate compound is effective in treating a given disease phenotype, was it the result of a reversal in expression of disease-related genes by the compound? This is difficult to assess given the complexity of the regulation of gene expression. Parameters such as drug dose and treatment times are critical for determining meaningful gene expression changes. Therefore, a range of doses and time points would need to be measured, and although the cost of whole genome sequencing is decreasing, to do this with the required samples sizes would be cost prohibitive. In addition to L1000 technology, the development of less expensive sequencing techniques, such TagSeq, improve feasibility to test this hypothesis which will provide important mechanistic insight into in silico gene mapping approaches (Lohman et al. 2016; Meyer et al. 2011 ).
Each of the six studies discussed in the previous paragraph used a different approach to identify a candidate compound that ameliorated disease phenotype when tested (Azim et al. 2017; Chandran et al. 2016; Ferguson et al. 2017; Mirza et al. 2017; Papassotiropoulos et al. 2013; Smalley et al. 2016) , and it is critical to identify the approach(s) with the greatest predictive accuracy. In other words, which choices at each of the main steps outlined above are the most likely to identify compounds that actually ameliorate the disease state? It is currently difficult to address this question because of the low-throughput nature of behavioral testing and the non-existence of gold standard data with which to benchmark various approaches.
A benchmark approach requires a gold standard dataset comprised of two components from the same population: (1) gene expression and/or genotyping data. Ideally, gene expression data would be obtained from multiple brain areas, cell types (single cell or cell-type transcriptomes), and tissue types (peripheral blood mononuclear cells (PBMCs), liver, gut microbiome, etc.) and (2) drug response. This should be the same measurement for each drug and there would ideally be a large range of drug effects. This continuous variable would lend itself to correlation analysis (rather than a binary measure of 0: drug was ineffective and 1: drug was effective). Drugs that are known to affect the phenotype (true positives) and drugs that are known to not effect phenotype (true negatives) should be present to assess how well the approach can discriminate (assign high scores to the true positives and poor scores to the true negatives). A benchmarking test-case scenario using this ideal gold standard dataset would systematically vary the input, algorithm, and prioritization scoring choice and assess the outputs for their predictability (Table 4) .
One caveat to this benchmarking strategy outlined here, is that it is unreasonable to assume that all compounds with therapeutic potential would be identified by in silico gene mapping. The best way to evaluate these approaches would be to take a heuristic testing strategy and select a few compounds nominated from various combinations at each of the three steps to test behaviorally, but as mentioned previously, behavioral testing is low throughput and this would be resource intensive.
As discussed before, the affected tissue (brain) is not available for testing until post-mortem, which certainly poses a problem if computational approaches that rely on gene expression measures are to be incorporated into drug repurposing/ personalized medicine endeavors for brain diseases. Moreover, analysis of postmortem brain expression is plagued with the Bchicken and the egg^conundrum. Meaning that it is impossible to know if the observed gene expression changes are the cause or the effect (due to years of alcohol use, for example) of the disease. This is one reason why animal models are key in studying brain diseases, and using animal models with high predictive validity for selecting therapeutic compounds is one way around this problem. Another option would be to identify a surrogate for brain gene expression, and this is an active area of research. Great hope has arrived with the discovery of inducible pluripotent stem cells (iPSCs) that can be differentiated into various neuronal types (Takahashi and Yamanaka 2006) . There are also methods that skip the induced pluripotent steps allowing direct conversion into functional neurons, called induced neurons (or iNs; for review, see Drouin-Ouellet et al. 2017) . Although these cell models hold promise for improving treatment of psychiatric diseases (Oni et al. 2016; Stern et al. 2017) , the protocols are long and tedious to produce adult-like neurons and the relevance to in silico gene mapping remains unexplored. Another surrogate for brain gene expression could be in peripherally accessible cell types, like PBMCs, especially considering the impressive evidence for immune involvement in AUD (for reviews, see Crews et al. 2017; de Timary et al. 2017; Mayfield and Harris 2017) . Another option that does not require access to brain tissue is imputing gene expression from GWAS summary data as discussed above . However, the latter approach has yet to be validated in vivo and will likely improve as the databases used to make the imputations improve, for example, by increasing samples in GTEx to better detect eQTLs. The GTEx Consortium plans to include up to 1000 donors in the final data release and collect complementary molecular data on subsets of samples, including epigenetic and protein data (GTEx Consortium et al. 2017) . Using GTEx data to impute transcriptomes for diverse groups of people should be approached with caution, as the donors are currently 83.7% European American and 15.1% African American (with the v7 Release) (GTEx Consortium et al. 2017 ).
Conclusion
The benefits of using computational strategies to transition to a more molecularly informed healthcare system are numerous. For example, diagnoses could be more precise and treatments more successful. Patients diagnosed with the same disease often represent a heterogeneous mixture of different underlying disorders, because there are numerous molecular disruptions that could lead to similar clinical presentations. This is especially true for AUD and other brain diseases, where a molecular readout of the affected organ is limited. It is no surprise, then, that the standard treatments fail for many because of incomplete knowledge regarding the underlying cause of a patient's disruptive symptoms. As we become more advanced in our ability to construct and interpret a molecular signature underlying disease symptoms, healthcare will advance toward personalized medicine, where each patient is treated to his or her individual profile.
The systems pharmacology approaches discussed in this Review have two main beneficial outcomes that should be considered independently. The first is an effective treatment and the other is mechanistic insight. It might be that the effectiveness of a compound is understood before its mechanism of action. However, progressing promising pharmaceutical treatment should not wait for the full understanding of the mechanism, as the mechanism underlying some of the most longstanding and successful treatments in medicine are still poorly understood (Letai 2017) . In fact, as suggested by (Hajjo et al. 2012) , one of the main benefits of this approach is to identify potentially therapeutic compounds without necessarily understanding the underlying target-specific mechanism.
Much hope has been placed on information contained within large genomic datasets and network approaches to drive clinical treatment toward personalized medicine and revolutionize healthcare. And, indeed, bioinformatics approaches have shown some success for identifying novel treatments for brain diseases. However, this research is still in its infancy, and many questions remain to be answered if these high expectations are to be met. Here, we have proposed the steps required for in silico gene mapping for the purpose of drug discovery and repurposing, reviewed state-of-the-art applications of these approaches to brain diseases, and highlighted some of the critical challenges facing the field. Success relies on the integration of enormous amounts of sequence and phenotype data from public and private sector sources. Ultimately, it will take a collaborative effort from academia, industry and government to advance drug development and repurposing for AUD (Litten et al. 2014 ).
